文献速递心律失常心力衰竭与心肌病

除颤器:为合适的患者选择合适器械

Defibrillators: Selecting the Right Device for the Right Patient.
PubMed 文献 · Circulation · 2016-01-01

综述比较经静脉ICD(含或不含CRT)、皮下ICD及可穿戴除颤器的适用人群与技术特点。经静脉ICD改善特定室颤/室速患者生存,S-ICD感染与导线并发症风险较低但不提供起搏,CRT-D适用于LVEF≤35%、QRS≥130ms且NYHA II-III或可走动IV级症状者。

要点

  • 经静脉ICD改善近致死性室颤复苏者及伴晕厥或收缩性心衰的持续性室速患者生存。
  • S-ICD感染与导线并发症风险较低,但不提供心动过缓或抗心动过速起搏。
  • CRT-D适用于LVEF≤35%、QRS≥130ms且NYHA II-III或可走动IV级症状者。

核心结论

  • 经静脉ICD、S-ICD和CRT-D各有适用人群,需根据患者特征选择合适器械以优化结局。
  • S-ICD主要优势为感染与导线并发症风险较低,但不提供起搏功能。
  • CRT-D可改善生存、生活质量及多项超声心动图指标,但存在30%无应答率。

研究设计与样本

  • 综述总结经静脉ICD、S-ICD、可穿戴除颤器及CRT-D的器械原理、适用患者特征与知识缺口。

主要发现

  • 多项随机临床试验显示经静脉ICD改善近致死性室颤复苏者及伴晕厥或收缩性心衰的持续性室速患者生存。
  • S-ICD不提供心动过缓或抗心动过速起搏,可能适合血管通路受限、高感染风险或某些先天性心脏病患者。
  • 多项随机对照试验显示CRT-D改善生存、生活质量及多项超声心动图指标。
  • CRT-D的主要挑战之一是30%无应答率。

关键数值与推荐

  • CRT-D适用于LVEF≤35%、QRS宽度≥130ms且NYHA II、III或可走动IV级症状者,尽管已接受指南导向药物治疗。
  • 经静脉ICD适用于近致死性室颤复苏者及伴晕厥或收缩性心衰(缺血性或非缺血性心肌病)的持续性室速患者,尽管已接受指南导向药物治疗。

临床怎么用

  • 对符合经静脉ICD适应证者,可评估S-ICD作为替代,尤其血管通路受限、高感染风险或某些先天性心脏病患者。
  • 选择CRT-D时需评估LVEF≤35%、QRS≥130ms及NYHA II-III或可走动IV级症状,并关注无应答风险。

局限性

  • 经静脉ICD在临床试验未纳入或代表性不足的亚组中的作用尚不明确。
  • S-ICD与经静脉ICD比较的有效性、所需除颤测试范围及与无导线起搏器等新技术的联合使用尚需更多数据。
  • CRT-D存在30%无应答率,需改进CRT与影像技术、患者选择和器械程控。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advances in the field of defibrillation have brought to practice different types of devices that include the transvenous implantable cardioverter-defibrillator (ICD) with or without cardiac resynchronization therapy, the subcutaneous ICD (S-ICD), and the wearable cardioverter-defibrillator. To ensure optimal use of these devices and to achieve best patient outcomes, clinicians need to understand how these devices work, learn the characteristics of patients who qualify them for one type of device versus another, and recognize the remaining gaps in knowledge surrounding these devices. The transvenous ICD has been shown in several randomized clinical trials to improve the survival of patients resuscitated from near-fatal ventricular fibrillation and those with sustained ventricular tachycardia with syncope or systolic heart failure as a result of ischemic or nonischemic cardiomyopathy despite receiving guideline-directed medical therapy. Important gaps in knowledge regarding the transvenous ICD involve the role of the ICD in patient subgroups not included, or not well represented, in clinical trials and the need to refine the selection criteria for the ICD in patients who are indicated for it. S-ICDs were recently introduced into the clinical arena as another option for many patients who have an approved indication for a transvenous ICD. The main advantage of the S-ICD is a lower risk of infection and lead-related complications; however, the S-ICD does not offer bradycardia or antitachycardia pacing. The S-ICD may be ideal for patients with limited vascular access, high infection risk, or some congenital heart diseases. However, more data are needed regarding the efficacy and effectiveness of the S-ICD in comparison to transvenous ICDs, the extent of defibrillation testing required, and the use of the S-ICD with other novel technologies, including leadless pacemakers. Cardiac resynchronization therapy-defibrillators are indicated in patients with a left ventricular ejection fraction ≤35%, QRS width ≥130 ms, and New York Heart Association class II, III, or ambulatory IV symptoms despite treatment with guideline-directed medical therapy. Multiple randomized controlled trials have shown that the cardiac resynchronization therapy-defibrillator improves survival, quality of life, and several echocardiographic measures. One main challenge related to cardiac resynchronization therapy-defibrillators is the 30% nonresponse rate. Many initiatives are underway to address this challenge including improved cardiac resynchronization therapy and imaging technologies and enhanced selection of patients and device programming.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Al-Khatib SM, Friedman P, Ellenbogen KA, et al. Defibrillators: Selecting the Right Device for the Right Patient. Circulation. 2016. PMID: 27799257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。